ADDF Announces Major Funding Commitment to Validate an Amyloid Blood Test for Non-Invasive Early Detection of Alzheimer’s
The Alzheimer’s Drug Discovery Foundation (ADDF) announced that it has awarded more than $2.2 million to C₂N Diagnostics to accelerate clinical validation and accreditation of its beta-amyloid blood test for early detection of Alzheimer’s disease pathology. C₂N's PrecivityAD™ will soon be a widely available blood test for Alzheimer's detection in people who are experiencing new onset memory loss. The company's St. Louis lab will begin processing tests prescribed by physicians and delivering results to aid in the diagnostic work-up process. The test involves a very small blood sample (as little as a teaspoon) from the arm. The latest ADDF funding will help C₂N gather important data needed to further advance the test's acceptability across a broad population.